CellBiotech: Regulating the Gut to Save the Kidneys, the 'Miracle' of the Gut-Kidney Axis Revealed by 'K-Probiotics'
Predicted impact: Low
Probiotic research feature; the same Duolac research was already covered recently.
Cell Biotech쎌바이오텍
049960 · KOSDAQ · ₩049960 · 쎌바이오텍
₩14,910▼ ₩90 (0.60%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y +27.22%
- Market cap
- ₩140B
- Enterprise value
- ₩44B
- P/E
- 8.3×
- P/B
- 1.0×
- Dividend yield
- 4.0%
- ROE
- 12.3%
- Net margin
- 27.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−19.4% from the high
₩11,350Today: ₩14,600 – ₩15,270₩18,500
Returns
- 1W−2.3%
- 1M−0.1%
- 3M−0.3%
- 6M−8.0%
- YTD+13.7%
- 1Y+27.2%
- Volume today
- 4,159
- 0.6× the 20-day average
- Traded today
- ₩61M
- Listed shares
- 9,400,000
- EPS (12 months)
- ₩1,787
- Earnings yield 12.0%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- MomentumFlat-1.6% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Cell Biotech stock overview
Cell Biotech (쎌바이오텍, KRX: 049960) is listed on KOSDAQ, in the Biotech & Pharma sector. Duolac operates in probiotics, microbiome and anticancer drug development. Its shares closed at ₩14,910 on Oct 27, 2026, down 0.60% on the day, giving it a market value of ₩140B.
Key facts
- Market cap
- ₩140B
- Sector
- Biotech & Pharma
- Latest price change
- −0.60%
- As of
- Oct 27, 2026
- Main business
- Duolac operates in probiotics, microbiome and anticancer drug development.
Quick answers about Cell Biotech
- What does Cell Biotech do?
- Duolac operates in probiotics, microbiome and anticancer drug development. Its probiotics business, which dates to 1995, sells raw powders and finished products such as Duolac-branded supplements and OEM/ODM products through B2B and B2C channels in Korea and abroad, and it is pursuing personalized probiotic products based on NGS testing. The company also develops microbiome-based functional foods and cosmetics, and is developing lactic acid bacteria drug delivery therapies for intractable intestinal diseases and colorectal cancer, with a colorectal cancer treatment in a Phase 1 clinical trial.
- What is the market cap of Cell Biotech?
- The market capitalisation of Cell Biotech was ₩140B at the close on Oct 27, 2026.
- Who are the largest shareholders of Cell Biotech?
- According to the latest official filings, the largest reported holders are Yoon Yeong-ok (3.83%, as of Dec 9, 2025); Yoon Seong-bae (2.45%, as of Feb 6, 2025); Jung Yu-suk (0.45%, as of Apr 2, 2025).
- When is the next earnings report from Cell Biotech?
- Korean companies rarely announce results dates in advance. Based on when Cell Biotech filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Cell Biotech?
- Yes. The National Pension Service held 0.00% of Cell Biotech shares as of Dec 31, 2020.
Company profile
Duolac operates in probiotics, microbiome and anticancer drug development. Its probiotics business, which dates to 1995, sells raw powders and finished products such as Duolac-branded supplements and OEM/ODM products through B2B and B2C channels in Korea and abroad, and it is pursuing personalized probiotic products based on NGS testing. The company also develops microbiome-based functional foods and cosmetics, and is developing lactic acid bacteria drug delivery therapies for intractable intestinal diseases and colorectal cancer, with a colorectal cancer treatment in a Phase 1 clinical trial.
Written by AI from the company's latest annual report.
- Korean name
- 쎌바이오텍
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 정명준
- Founded
- Feb 1995
- Listed
- Dec 2002
- Listed shares
- 9,400,000
- Fiscal year ends
- Month 12
- Website
- www.cellbiotech.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
CellBiotech's Duolac: CBT Probiotic Shown to Improve Chronic Kidney Disease Mechanism
Predicted impact: Low
Probiotic mechanism research; early-stage with no disclosed financial impact.
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earnings (consolidated)Aug 7, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Preliminary earnings (consolidated)May 8, 2026
- Corporate value-up planMar 27, 2026
Titles in Korean until English translations are added.
Also known as: Cell Biotech / 쎌바이오텍 / 049960 / KRX:049960
Source: KRX statistical information